TFS Capital’s abrdn Life Sciences Investors HQL Stock Holding History

TFS Capital’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-21,591	Closed	-$404K	–	807
2016 Q3	$404K	Buy	+21,591	New	+$407K	0.1%	295
2015 Q2	–	Sell	-10,871	Closed	-$300K	–	986
2015 Q1	$300K	Buy	+10,871	New	+$296K	0.03%	680
2014 Q3	–	Sell	-77,090	Closed	-$1.6M	–	1108
2014 Q2	$1.6M	Buy	+77,090	New	+$1.62M	0.13%	245

Other funds holding HQL

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

TFS Capital's HQL Position: Q4 2016 in Review

TFS Capital sold out of abrdn Life Sciences Investors (HQL) in Q4 2016, closing a stake of 21,591 shares — an estimated $404K sold.

TFS Capital first reported a position in HQL in Q2 2014 and held it in 3 quarters. The position peaked at $1.6M in Q2 2014. 49 funds tracked by Wall St. Rank hold HQL as of Q4 2016.

TFS Capital reported no remaining abrdn Life Sciences Investors position as of Q4 2016 after selling out during the quarter.
TFS Capital sold 21,591 abrdn Life Sciences Investors shares in Q4 2016, an estimated $404K.
TFS Capital first reported a position in abrdn Life Sciences Investors in Q2 2014 and held it in 3 quarters.
TFS Capital's abrdn Life Sciences Investors position peaked at $1.6M in Q2 2014.
49 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.